vs
Side-by-side financial comparison of ACNB CORP (ACNB) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
ACNB CORP is the larger business by last-quarter revenue ($47.2M vs $27.5M, roughly 1.7× Sanara MedTech Inc.). ACNB CORP runs the higher net margin — 22.9% vs -5.9%, a 28.7% gap on every dollar of revenue. On growth, ACNB CORP posted the faster year-over-year revenue change (42.2% vs 4.6%). ACNB CORP produced more free cash flow last quarter ($52.6M vs $3.9M). Over the past eight quarters, ACNB CORP's revenue compounded faster (22.1% CAGR vs 21.8%).
ACNB Corp is a US-based financial holding company headquartered in Pennsylvania. It provides a full suite of financial solutions including retail and commercial banking, wealth management, trust services, and property & casualty insurance products. Its core market covers local communities, individual consumers, and small-to-medium enterprises across south-central Pennsylvania and northern Maryland.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
ACNB vs SMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $47.2M | $27.5M |
| Net Profit | $10.8M | $-1.6M |
| Gross Margin | — | 93.2% |
| Operating Margin | 27.9% | 23.5% |
| Net Margin | 22.9% | -5.9% |
| Revenue YoY | 42.2% | 4.6% |
| Net Profit YoY | 63.8% | 5.3% |
| EPS (diluted) | $1.10 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $47.2M | $27.5M | ||
| Q3 25 | $50.9M | $26.3M | ||
| Q2 25 | $50.3M | $25.8M | ||
| Q1 25 | $43.5M | $23.4M | ||
| Q4 24 | $33.2M | $26.3M | ||
| Q3 24 | $34.1M | $21.7M | ||
| Q2 24 | $33.3M | $20.2M | ||
| Q1 24 | $31.6M | $18.5M |
| Q4 25 | $10.8M | $-1.6M | ||
| Q3 25 | $14.9M | $-30.4M | ||
| Q2 25 | $11.6M | $-2.0M | ||
| Q1 25 | $-272.0K | $-3.5M | ||
| Q4 24 | $6.6M | $-1.7M | ||
| Q3 24 | $7.2M | $-2.9M | ||
| Q2 24 | $11.3M | $-3.5M | ||
| Q1 24 | $6.8M | $-1.8M |
| Q4 25 | — | 93.2% | ||
| Q3 25 | — | 92.9% | ||
| Q2 25 | — | 92.5% | ||
| Q1 25 | — | 92.2% | ||
| Q4 24 | — | 91.4% | ||
| Q3 24 | — | 90.8% | ||
| Q2 24 | — | 90.0% | ||
| Q1 24 | — | 89.8% |
| Q4 25 | 27.9% | 23.5% | ||
| Q3 25 | 37.2% | 11.2% | ||
| Q2 25 | 29.7% | -0.1% | ||
| Q1 25 | -1.3% | -8.9% | ||
| Q4 24 | 24.8% | 18.6% | ||
| Q3 24 | 27.6% | 3.6% | ||
| Q2 24 | 42.8% | -14.3% | ||
| Q1 24 | 26.9% | -8.3% |
| Q4 25 | 22.9% | -5.9% | ||
| Q3 25 | 29.2% | -115.5% | ||
| Q2 25 | 23.2% | -7.8% | ||
| Q1 25 | -0.6% | -15.1% | ||
| Q4 24 | 19.9% | -6.5% | ||
| Q3 24 | 21.1% | -13.2% | ||
| Q2 24 | 33.9% | -17.4% | ||
| Q1 24 | 21.4% | -9.5% |
| Q4 25 | $1.10 | $-0.32 | ||
| Q3 25 | $1.42 | $-3.40 | ||
| Q2 25 | $1.11 | $-0.23 | ||
| Q1 25 | $-0.03 | $-0.41 | ||
| Q4 24 | $0.77 | $-0.18 | ||
| Q3 24 | $0.84 | $-0.34 | ||
| Q2 24 | $1.32 | $-0.41 | ||
| Q1 24 | $0.80 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $65.6M | $16.6M |
| Total DebtLower is stronger | $255.4M | $46.0M |
| Stockholders' EquityBook value | $420.0M | $5.9M |
| Total Assets | $3.2B | $72.9M |
| Debt / EquityLower = less leverage | 0.61× | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $65.6M | $16.6M | ||
| Q3 25 | $102.1M | $14.9M | ||
| Q2 25 | $103.1M | $17.0M | ||
| Q1 25 | $123.6M | $20.7M | ||
| Q4 24 | $47.3M | $15.9M | ||
| Q3 24 | $58.1M | $16.3M | ||
| Q2 24 | $86.3M | $6.2M | ||
| Q1 24 | $53.1M | $2.8M |
| Q4 25 | $255.4M | $46.0M | ||
| Q3 25 | $255.4M | $45.1M | ||
| Q2 25 | $255.4M | $44.2M | ||
| Q1 25 | $255.3M | $43.4M | ||
| Q4 24 | $255.3M | $30.7M | ||
| Q3 24 | $255.3M | $30.1M | ||
| Q2 24 | $255.3M | $14.4M | ||
| Q1 24 | $255.3M | $9.7M |
| Q4 25 | $420.0M | $5.9M | ||
| Q3 25 | $408.6M | $6.1M | ||
| Q2 25 | $395.2M | $35.4M | ||
| Q1 25 | $386.9M | $36.7M | ||
| Q4 24 | $303.3M | $39.4M | ||
| Q3 24 | $306.8M | $39.8M | ||
| Q2 24 | $289.3M | $41.7M | ||
| Q1 24 | $279.9M | $43.3M |
| Q4 25 | $3.2B | $72.9M | ||
| Q3 25 | $3.3B | $71.1M | ||
| Q2 25 | $3.3B | $98.8M | ||
| Q1 25 | $3.3B | $96.4M | ||
| Q4 24 | $2.4B | $88.1M | ||
| Q3 24 | $2.4B | $88.5M | ||
| Q2 24 | $2.5B | $73.4M | ||
| Q1 24 | $2.4B | $70.9M |
| Q4 25 | 0.61× | 7.74× | ||
| Q3 25 | 0.62× | 7.33× | ||
| Q2 25 | 0.65× | 1.25× | ||
| Q1 25 | 0.66× | 1.18× | ||
| Q4 24 | 0.84× | 0.78× | ||
| Q3 24 | 0.83× | 0.76× | ||
| Q2 24 | 0.88× | 0.34× | ||
| Q1 24 | 0.91× | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $53.6M | $3.9M |
| Free Cash FlowOCF − Capex | $52.6M | $3.9M |
| FCF MarginFCF / Revenue | 111.4% | 14.0% |
| Capex IntensityCapex / Revenue | 2.3% | 0.3% |
| Cash ConversionOCF / Net Profit | 4.96× | — |
| TTM Free Cash FlowTrailing 4 quarters | $92.2M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.6M | $3.9M | ||
| Q3 25 | $23.2M | $2.2M | ||
| Q2 25 | $17.8M | $2.7M | ||
| Q1 25 | $-71.0K | $-2.0M | ||
| Q4 24 | $39.8M | $932.0K | ||
| Q3 24 | $13.6M | $2.1M | ||
| Q2 24 | $9.7M | $-1.4M | ||
| Q1 24 | $10.8M | $-1.6M |
| Q4 25 | $52.6M | $3.9M | ||
| Q3 25 | $22.8M | $1.1M | ||
| Q2 25 | $17.6M | $902.7K | ||
| Q1 25 | $-730.0K | $-3.7M | ||
| Q4 24 | $38.8M | $859.9K | ||
| Q3 24 | $13.3M | $2.0M | ||
| Q2 24 | $9.4M | $-1.5M | ||
| Q1 24 | $10.7M | $-1.7M |
| Q4 25 | 111.4% | 14.0% | ||
| Q3 25 | 44.7% | 4.2% | ||
| Q2 25 | 35.0% | 3.5% | ||
| Q1 25 | -1.7% | -15.9% | ||
| Q4 24 | 117.0% | 3.3% | ||
| Q3 24 | 39.1% | 9.4% | ||
| Q2 24 | 28.3% | -7.3% | ||
| Q1 24 | 33.9% | -9.0% |
| Q4 25 | 2.3% | 0.3% | ||
| Q3 25 | 0.8% | 4.0% | ||
| Q2 25 | 0.4% | 6.8% | ||
| Q1 25 | 1.5% | 7.4% | ||
| Q4 24 | 2.9% | 0.3% | ||
| Q3 24 | 0.7% | 0.0% | ||
| Q2 24 | 0.9% | 0.3% | ||
| Q1 24 | 0.2% | 0.4% |
| Q4 25 | 4.96× | — | ||
| Q3 25 | 1.56× | — | ||
| Q2 25 | 1.52× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.03× | — | ||
| Q3 24 | 1.88× | — | ||
| Q2 24 | 0.86× | — | ||
| Q1 24 | 1.60× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACNB
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
